Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Salat

Showing results (41-50 of 42) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 42 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgeryM Untch, P A Fasching, G E Konecny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†G von Minckwitz, S Loibl, M Untch, et al.
Pageof 5

Showing results (41-50 of 42) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 42 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgeryM Untch, P A Fasching, G E Konecny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†G von Minckwitz, S Loibl, M Untch, et al.
Pageof 5